Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
about
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid CancerCD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.Current and future immunotherapies for thyroid cancer.Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
P2860
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combining BRAF inhibitor and a ...... l of anaplastic thyroid cancer
@en
Combining BRAF inhibitor and a ...... of anaplastic thyroid cancer.
@nl
type
label
Combining BRAF inhibitor and a ...... l of anaplastic thyroid cancer
@en
Combining BRAF inhibitor and a ...... of anaplastic thyroid cancer.
@nl
prefLabel
Combining BRAF inhibitor and a ...... l of anaplastic thyroid cancer
@en
Combining BRAF inhibitor and a ...... of anaplastic thyroid cancer.
@nl
P2093
P2860
P356
P1433
P1476
Combining BRAF inhibitor and a ...... l of anaplastic thyroid cancer
@en
P2093
Eran Brauner
Gordon James Freeman
Kate Virginia Dennett
Pierre Vanden Borre
Salma Amin
Sareh Parangi
Viswanath Gunda
Yon Seon Kim
P2860
P304
17194-17211
P356
10.18632/ONCOTARGET.7839
P407
P577
2016-03-02T00:00:00Z